The New York Entrepreneur

European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai

Read Time:6 Second

The committee said Leqembi’s effect on delaying cognitive decline does not outweigh “the risk of serious side effects associated with the medicine.”

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Fed’s key inflation gauge rose 2.5% in June from a year ago, in line with expectations
Next post LVMH CEO Bernard Arnault says Olympics sponsorship honors the spirit of France